Summary

Market Overview
The Global Organ-On-Chip Market reached US$ 107.5 million in 2022 and is expected to reach US$ 796.7 million by 2030 and is expected to grow with a CAGR of 29.6% during the forecast period 2023-2030. The organ-on-chip market trends show large adoption of organ-on-chip for drug discovery owing to the rising prevalence of disorders and increasing research and development.
The organ-on-chip market scope comprises models segmented as a liver-on-chip model, lung-on-chip model, kidney-on-chip model, tumor models, heart-on-chip model, custom & multi-organ-on-chip models and others, which has increased the organ-on-chip market share. The main advantage of organ-on-a-chip technology is the facility to create a detailed human model that has operational reactions on the level of organs or tissues, thereby bypassing the usage of animal models, as well as immensely enhancing new drug discovery operations for personal healthcare.
The global market for organ-on-chip is expanding as a result of factors including the increasing market developments and the need for an alternative to animal testing in drug development and the presence of supportive guidelines and approvals for organ-on-chip in drug design and development. On January 17, 2023, CN Bio Innovations Ltd announced that the FDA and CN Bio Innovations Ltd are expanding the partnership for the second time. The new research will use the PhysioMimix Multi-organ System to assess multi-organ MPS and their applications.
Market Dynamics
Organ-On-Chip Model an Alternative to Animal Testing Drives The Growth Of The Organ-on-Chip Market.
Further to the suffering of the true investigations, animals in laboratories are denied everything realistic and crucial to them, they are restricted to empty cells, socially secluded, and psychologically traumatized. The conscious and emotional beings used in research are treated in the same manner as disposable lab equipment. The bulk of animal research does not improve human health, and it is questionable how much of an impact animal research has on most medical developments.
Also, the presence of stringent regulatory policies and laws is pushing researchers to opt for alternatives to animal testing. For instance, the Animal Welfare Act, or AWA, is a federal regulation that handles the criterion of maintenance animals acquire at investigation establishments. This regulation bans approximately 95% of the animals tested like birds, rats, fish, reptiles, and mice, and delivers only minimal protection for the rest. Labs are not needed to report non-AWA-protected animals.
Increasing Market Development Creates Lucrative Opportunities For Manufacturers.
The global market expansion in the anticipated term is being driven by the rising number of market advancements, including product launches, partnerships, acquisitions and mergers in the organ-on-chip industry. For instance, in May 2022, organ-on-a-chip designer Emulate Inc. introduced an elevated offering for investigators researching inflammatory bowel disorder with its tissue model that permits the demonstration of how immune cells are triggered and distributed in the body.
Additionally, in April 2022, Valo Health completed the acquisition of TARA Biosystems, designers of a 3D cardiac tissue modeling platform. Valo intended to integrate TARA’s cardiac tissue chips into an end-to-end drug design offering strived at cardiovascular disorder, pushed by its Opal data platform. Similarly, in September 2022, the CiRA research team developed an airway-on-a-chip that enacts respiratory organs employing endothelial cells from airway tissue and vascular tissue.
Availability of Substituents Will Hamper The Growth Of The Market.
The existence of an alternative to organs-on-chips on the market is impeding the expansion of the global market throughout the anticipated time. The market's abundance of organoids, which have the similar function of simulating tissue and organ physiology, is a significant barrier to the expansion of the organ-on-chip industry over the forecast period.
For instance, in February 2023, Molecular Devices, LLC., a top provider of high-performance life science products, and HUB Organoids (HUB), the frontiers in the domain of adult stem cell-derived organoids, formed a collaboration aimed at aiding the persistent development of next-generation 3D biology technologies that facilitates a step-change deduction in pre-clinical to clinical drug attrition.
COVID-19 Impact Analysis
Before the COVID-19 pandemic, organ-on-chip was employed in drug design and development to a limited extent but during the initial period, the number of infected individuals was increasing exponentially, and the unavailability of particular diagnostic and treatments called for increased research and development activities which led to growth in the adoption of organ-on-chip devices.
For instance, although animal prototypes and monolayer cell cultures were employed for pathogenesis investigations and the design of COVID-19 treatment, bioengineered organs-on-chips, and stem cell organoids have appeared as two cutting-edge technologies utilized to create biomimetic in vitro three-dimensional (3D) tissue or organ prototypes.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global organ-on-chip market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global organ-on-chip market growth over the forecast period.
Segment Analysis
The global organ-on-chip market is segmented based on model, application, end user and region.
Drug Discovery From the Application Segment Accounts For 49.4% Of Market Share Owing To Rising Research And Development.
Compared to conventional 2D cell cultures, organ-on-chip platforms can be employed for high-throughput screening of drug candidates in an environment that is more physiologically realistic. Organ-on-chip platforms enable researchers to test and assess the safety and efficacy of drug candidates in a more realistic environment by simulating the microenvironment and functional characteristics of certain organs or tissues. Earlier in the drug discovery process, this can assist uncover possible lead compounds or eliminate hazardous or ineffective candidates, saving time and resources.
The pharmacokinetics (PK) of drug candidates, including their absorption, distribution, metabolism, and excretion (ADME) characteristics, can be studied using organ-on-chip platforms in a more physiologically comparable setting. In addition, almost 44,000 Americans have drug-induced liver infections (DILI). Therefore, creating a liver-on-a-chip technology would be crucial for several diagnostic and therapeutic fields, especially for creating novel treatments for long-term illnesses like hepatitis B, liver cirrhosis, and hepatocellular cancer.
Geographical Analysis
North America Accounted For Approximately 44.8% Of The Market Share Owing To The Strong Presence Of Major Players And Increasing Technological Advancements.
Manufacturers have chances to expand their operations in this region because of the rising demand for organ-on-chip for advancements in North America. The area has many producers and its rapid economic development has raised industrial production of organ-on-chips models. Using cutting-edge technologies, such as 3D bioprinting, Organovo Holdings, Inc., a company that specializes in three-dimensional (3D) biology, successfully took its first inflammatory bowel disease model toward the next stage of target discovery and validation for Crohn's disease.
Furthermore, the growing partnership, adoption and awareness initiatives for organ-on-chip are also contributing to the growth of the regional market in the forecast period. For instance, on May 19, 2021, the collaboration between InSphero AG, a leader in 3D cell-based assay technology, and Hamilton, a leading provider of automated liquid handling equipment, aims to enhance the creation and management of 3D microtissues (spheroids). These factors show the dominance of North America.
Competitive Landscape
The major global players in the organ-on-chip market include Emulate Inc., Organovo Holdings, Mimetas B.V., AxoSim, Inc., Insphero, CN Bio Innovations Ltd, TissUse GmbH, Hesperos Inc., and Nortis, Inc. among others.
Why Purchase the Report?
• To visualize the global organ-on-chip market segmentation based on model, application, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of organ-on-chip market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global organ-on-chip market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents